TrivarX Limited (MDBIF) Fair Value & Analysis
Healthcare · US · Market cap $3.0M
TrivarX Limited
MDBIF · US
Fair value as of: Jun 26, 2026
From 8 valuation models · updated 7 days ago
Fair value updated Jun 26, 2026 — revised from $0.0300 to $0.0026 (−91.4%) since Jun 24, 2026.
Price vs Fair Value (12 months)
12‑month range $0.0025 – $0.0244 · fair‑value band $0.0025 – $0.0026 · the $0.0026 price screens above the $0.0026 fair value. As of Jun 26, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
TrivarX Limited (MDBIF) currently trades at $0.0026, while our model-based Fair Value estimate is $0.0026 — implying the stock looks roughly 0.8% overvalued today. We read business quality at 38/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).
It earns a return on equity of -12.1%. The balance sheet holds a net cash position of $1.1M. Fundamentals as of Jun 26, 2026
Key figures & financial health
Figures from reported company fundamentals (EODHD) · as of Jun 26, 2026. TTM = trailing twelve months.
About the company
TrivarX Limited, a health technology company, engages in the development of AI-driven, scientifically-based devices for screening and diagnosis of behavioral health conditions in Australia and the United States. The company offers mental well-being solutions for businesses through corporate health product; and develops products for healthcare provider market. The company was formerly known as Medibio Limited and changed its name to TrivarX Limited in October 2023. TrivarX Limited was incorporated in 1987 and is based in Hawthorn East, Australia.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
TrivarX Limited reported revenue of $1.1M in FY2025 versus $1.3M in FY2021, a compound −2.8%/yr. Reported net income was −$943K in FY2025.
Is MDBIF fairly valued? → Check now
Similar stocks
6 more Health Information Services stocks, each showing price versus our Fair Value estimate (as of Jun 26, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Veeva Systems Inc VEEV | $172.61 | $104.16 | -40% |
| Pro Medicus Limited PME | A$161.58 | A$33.82 | -79% |
| BrightSpring Health Services, Inc BTSG | $67.20 | $26.39 | -61% |
| Tempus AI, Inc TEM | $48.61 | $12.67 | -74% |
| HealthEquity, Inc HQY | $84.92 | $56.63 | -33% |
| M3, Inc MTHRY | $5.03 | $7.44 | +48% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is TrivarX Limited (MDBIF) undervalued?
What is the fair value of MDBIF?
What is the quality score of MDBIF?
What is the net profit margin of MDBIF?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.